veldona

VELDONA is a proprietary low-dose oral formulation of interferon-alpha developed by Ainos. It is designed for oromucosal (sublingual and buccal) delivery to activate immune responses at ultra-low doses, minimizing systemic side effects commonly associated with injectable interferons. The drug leverages nearly four decades of research and aims to provide broad-spectrum antiviral efficacy as well as immunomodulatory benefits in both human and animal health. Its innovative delivery mechanism eliminates the need for injections and cold chain logistics, offering flexible dosage forms such as lozenges, tablets, films, and sprays. VELDONA has demonstrated potential in treating rare diseases like Sjögren's syndrome (autoimmune), HIV-related oral warts (orphan indication), the common cold, COVID-19 (coronavirus infections), and other viral or immune-related conditions[2][3][6][8]. Clinical trials have shown significant symptom alleviation with a strong safety profile[5][8].

Brand names

VELDONA

Other names

veldonalow-dose oral interferon-alphaoral interferon-alphaveldona oral interferon